All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
The 23rd Congress of the European Hematology Association (EHA) will be held in Stockholm, Sweden at the Stockholmsmässan Congress Center from 14–17 June 2018. Abstract submission is due to close on 1 March 2018 at 23:59 CET; the deadline for EHA attendance registration is 10 May 2018.
On the EHA website, it states that: “the 23rd Congress of EHA will offer you a program covering every subspecialty in hematology, as well as network opportunities with experts from all over the globe. The educational and scientific program will highlight state-of-the-art clinical practice, the latest findings in hematology research and many more interesting sessions. The Congress also provides satellite programs, Updates-in-Hematology and an exhibition organized by pharmaceutical companies."
The Multiple Myeloma Hub will be covering key highlights from EHA 2018 during the congress including oral sessions, late-breaking abstracts, and educational sessions, with a focus on the latest lymphoma research that impacts clinical practice.
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox